| |
With the emergence of precision medicine and its focus on customizing treatment to individual patients, it may be possible to reduce the time to diagnosis for rare conditions, enabling identification and intervention at earlier stages of the disease – a hope that is new for rare disease patients. Explore this and more in our latest blog.
|
|
Today's Big NewsMar 20, 2023 |
| By Nick Paul Taylor For Sangamo, last week is probably one to forget. Late on Friday, the gene-based therapy biotech revealed it had lost two partners in quick succession, with Biogen and Novartis walking away from partnerships collectively worth billions of dollars in milestones within days of each other. |
|
|
|
By Gabrielle Masson As Athenex’s cash dries up, the FDA has slapped a clinical hold on its phase 1 trial assessing a CAR-NKT cell therapy for neuroblastoma in the wake of a patient death. |
By Andrea Park Since its humble beginnings back in 2012, the Fierce 15 has made a point of spotlighting the most exciting startups in medtech—those not only challenging the limits of both the tech and healthcare industries but also making real progress toward their lofty goals. The companies on this year’s list—which kicks off the second decade of Fierce Medtech’s Fierce 15—are setting the bar even higher. |
Sponsored by DrugBank Data rich but quality poor. Massive amounts of disorganized data might be the final roadblock to unlocking the potential of data-centric AI. |
By James Waldron After more than six years, Zymeworks and Daiichi Sankyo have agreed to amicably part ways from an immune-oncology agreement that once had the potential to bring in $293 million in biobucks. |
By Max Bayer BioNTech is making it clear that the company is working to become a cancer-treating powerhouse. A licensing deal for OncoC4's CTLA4-targeting antibody is the latest in a string of recent moves. |
By Nick Paul Taylor Takeda has revealed the data that persuaded it to pay $4 billion upfront for Nimbus Therapeutics’ TYK2 inhibitor. The highest dose completely cleared psoriasis in one-third of patients, adding weight to claims that the candidate is an improvement on Bristol Myers Squibb’s rival drug Sotyktu. |
By James Waldron Momentum continues to build for Karuna’s much-hyped schizophrenia therapy, with the company revealing another late-stage win. Yet, a secondary endpoint fail and a share price wobble were a reminder that the anticipated U.S. approval this year isn't yet in the bag. |
By Joseph Keenan Syneos Health inked a multiyear deal with Microsoft to further develop a platform that leverages machine learning to support and speed the analysis, design and operations of clinical trials. |
By Angus Liu Under David Ricks’ leadership, Eli Lilly’s stock price reached a record high in 2022. But the CEO’s pay decreased slightly last year. |
By Fraiser Kansteiner Ozempic, which has been in short supply for some six months, is once again available in two common, lower doses, while a third higher dose will maintain limited availability through the end of the month, according to the U.S. Food and Drug Administration’s drug shortage database. Novo Nordisk confirmed the restocking in an emailed statement. |
By Andrea Park The FDA cleared a pair of tests this week both aimed specifically at improving diagnoses of women’s health conditions. |
By Paige Minemyer The NCAA basketball tournament is officially underway, and that means the Fierce Healthcare team is back with another bracket competition as well. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss the SVB failure, what to expect next and what it all meant for the biotech industry. We also cover Pfizer's big acquisition, insulin prices and more of this week's top headlines. |
|
|---|
|
|
|
May 1 - 3, 2023 | Jersey City, NJ Don’t miss the opportunity to gain best practices in medical affairs strategy development and ensuring scientific materials are created and shared in a regulatory compliant manner to internal/external stakeholders and thought leaders. Register Today & save $200 from now until April 7th!
|
|
| Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| Executive SummaryRead about the latest survey results from over 200 biopharma executives and the changing approaches to building biologic drug development pipelines. Sponsored by: Twist Bioscience |
| WhitepaperHave you had your questions about mRNA/saRNA manufacturing unanswered during a webinar; have no fear, we have you covered here. Sponsored by: Aldevron |
| Whitepaper Download Herspiegel Consulting’s Go-To-Market Model, based on 100+ launches, to learn the critical components, and timelines for commercial success. Sponsored by: Herspiegel Consulting |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| Research Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development. Sponsored by: Catalent |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
